Peptide GPS

Industry & Regulation

ADA 2026: the GLP-1 and obesity findings that matter for patients

The ADA 86th Scientific Sessions (June 5-8, New Orleans) produced notable GLP-1 data. Here's what matters — and what remains under investigation.

4 min read · Updated 2026-06-13

Peptide GPS publishes educational information, not medical advice. We don't sell, prescribe, or recommend specific medications, dosages, or providers. Always discuss any therapy with a licensed clinician.

Key takeaways

  • ADA 2026 was held June 5-8, 2026 in New Orleans — not Chicago
  • Aleniglipron's Phase 2b results were simultaneously published in Nature Medicine and presented at ADA — the most rigorously sourced new finding
  • CagriSema REIMAGINE 1, 2, 3 data in type 2 diabetes was presented — combination therapy still under FDA review
  • Lean mass and body composition data was a major conference theme — evidence is evolving
  • Conference presentations are not peer-reviewed findings: distinguish carefully

The scope of ADA 2026

The ADA 86th Scientific Sessions included presentations across pharmacotherapy, management, GLP-1 pipeline drugs, , cardiovascular outcomes, and diabetes technology. This article focuses on findings with peer-reviewed primary sources or official trial data.

Oral GLP-1 pipeline: what the aleniglipron data showed

The clearest new finding with a peer-reviewed primary source is aleniglipron. Structure Therapeutics simultaneously published Phase 2b results in Nature Medicine (June 7, 2026) and presented at ADA 2026.

The Phase 2b ACCESS trial enrolled 230 adults with obesity and tested once-daily oral aleniglipron at three doses, or , over 36 weeks:

  • 120 mg: 11.3% placebo-adjusted weight loss at 36 weeks
  • 90 mg: 9.8%
  • 45 mg: 8.2%

Weight loss continued without plateau at trial's end. GI events were mild to moderate, decreasing over time. Treatment-related discontinuations: 10.4%. No drug-induced liver injury.

Aleniglipron is . No NDA filed. Two oral GLP-1s are today: Foundayo (orforglipron) and oral semaglutide.

CagriSema: REIMAGINE 1, 2, 3

Novo Nordisk presented data from the REIMAGINE trials — evaluating cagrilintide combined with semaglutide (CagriSema) for type 2 diabetes. The symposium was chaired by Dr. John Buse and covered REIMAGINE 1, 2, and 3.

CagriSema combines semaglutide (GLP-1 ) with cagrilintide (an amylin analogue). Earlier REDEFINE obesity trials showed approximately 23% weight loss, but REDEFINE 4 found CagriSema failed to demonstrate non-inferiority to tirzepatide in a head-to-head comparison. The REIMAGINE trials in type 2 diabetes are a separate program.

An NDA for CagriSema is under FDA review as of June 2026. It has not been approved.

Lean mass and body composition data

Body composition — how much GLP-1 users lose alongside fat — was one of the most discussed themes at ADA 2026. The core finding from current evidence: GLP-1 users do lose some lean mass during weight loss, consistent with any significant calorie-deficit-driven weight loss. The proportion relative to total weight loss remains debated.

Several presentations addressed newer therapies targeting muscle preservation alongside GLP-1 activity. This area is genuinely evolving. Most lean mass presentations at ADA 2026 were conference-only — peer-reviewed publications should be verified before drawing clinical conclusions.

during GLP-1 therapy continues to be consistently recommended by clinicians as a practical mitigation strategy; ADA 2026 adds context but does not change this recommendation.

What the conference didn't resolve

Which oral GLP-1 is best: No head-to-head published trial data exists between aleniglipron, orforglipron, and oral semaglutide.

Whether CagriSema will be approved: The FDA review is ongoing.

Long-term cardiovascular outcomes for newer agents: SELECT data remains the gold standard. Equivalent data for tirzepatide (SURMOUNT-MMO) and newer agents is pending.

Questions to ask your clinician

  • Did any ADA 2026 presentation change the clinical recommendation for my current GLP-1 or dose?
  • Is the lean mass question relevant to my situation, and what does my prescriber recommend about resistance training?
  • If CagriSema is approved, would it be appropriate for my health profile?

ADA presentations are a preview — the full picture comes through peer review, full publications, and regulatory decisions. If something from ADA 2026 seems relevant to your treatment, bring the specific finding to your prescriber.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

Get the weekly brief

One plain-English email per week on GLP-1s, peptides, and the regulation around them.

Related reading

Medications

TRIUMPH-1 decoded: what retatrutide's Phase 3 results actually mean

Medications

A third oral GLP-1 is in the pipeline. Here's what the Phase 2b data shows.

Medications

Why the oral Wegovy pill is 25mg, not 50mg: what OASIS 4 shows